PCRX Q4 2019 Earnings — Pacira BioSciences, Inc. Revenue & Financial Results | Market Cap Arena

PCRXPacira BioSciences, Inc.

$969M

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$122M+28.7% YoY

Gross Profit

$91M73.9% margin

Operating Income

$2M1.4% margin

Net Income

-$5M-4.0% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+16.9%

Cash Flow

Operating Cash Flow

$26M

Free Cash Flow

$21M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$831M

Total Liabilities

$476M

Stockholders' Equity

$355M

Cash & Equivalents

$78M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$122M	$95M	+28.7%
Gross Profit	$91M	$71M	+27.3%
Operating Income	$2M	$12M	-86.0%
Net Income	-$5M	$8M	-159.0%

Revenue Segments

Product

$122M100%

Royalty

$578,0000%